Apelix: an innovative drug targeting specific breast cancers and its indications

Alpelisib (Alpelisib) is an innovative targeted therapy drug that belongs to the PI3K inhibitor family and is specifically designed to combat specific types of breast cancer. Its unique indications make it unique in the field of breast cancer treatment. Specifically, Apelvis combined with fulvestrant is approved for the treatment of patients with hormone receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative advanced or metastatic breast cancer who carry mutations in the catalytic phosphatidylinositol-3-kinase subunit alpha (PIK3CA). This indication covers postmenopausal female and male patients who have tumors containing the above-mentioned mutations as confirmed by an FDA-approved diagnostic test (such as the therascreen PIK3CA RGQ PCR Kit) during or after receiving endocrine-based therapy.

Apelix's mechanism of action is to block the overactivated PI3K pathway, which provides energy to cells under normal circumstances, but in the case of PIK3CA gene mutations, it may promote the survival and growth of cancer cells. By inhibiting this pathway, Apelvis aims to selectively kill cancer cells, particularly those harboring PIK3CA mutations. Notably, Apelvis specifically targets the alpha isoform of PI3K, a specific form of the protein produced by different mutations in the PIK3CA gene.

Before taking Apelvis, it is critical that patients have their cancer tested to ensure that their tumors indeed have the PIK3CA mutation. This is because the efficacy of apelvis is largely dependent on the presence of this specific mutation. Advanced breast cancer refers to cancer that has come back or spread to the chest wall below the breast, while metastatic breast cancer refers to advanced cancer that has spread to other parts of the body.